Obesity is a significant global health problem and has been associated with altered
pharmacokinetics and pharmacodynamics of many drugs. However, little is known regarding …

The increased prevalence of obesity presents challenges for clinicians aiming to provide
optimised antimicrobial dosing in the intensive care unit. Obesity is likely to exacerbate the …

The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …

The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Background Evidence on pharmacokinetic/pharmacodynamic (PK/PD) alterations and
clinical outcomes in obese patients with serious infections remains limited. This study aimed …

Obesity is a significant global public health concern that is associated with an elevated risk
of comorbidities as well as severe postoperative and nosocomial infections. The treatment of …

Objectives: Obesity may alter the pharmacokinetics of β-lactams. The goal of this study was
to evaluate if and why serum concentrations are inadequate when standard β-lactam …

Physiologic alterations seen in obesity commonly impact the pharmacokinetics (PK) and
pharmacodynamics (PD) of antibiotics and may result in suboptimal dosing in this …

Abstract Background and Objective Standard piperacillin–tazobactam (PT) dosing may be
suboptimal in obesity, but high-dose regimens have not been studied. We prospectively …

What is known and objective Obesity is a significant burden on the healthcare system in the
U nited S tates, and determining the appropriate antimicrobial dosing regimen in morbidly …